Integrated framework of fragment-based method and generative model for lead drug molecules discovery

被引:0
作者
Chude-Okonkwo, Uche A.K. [1 ]
Lehasa, Odifentse [1 ]
机构
[1] Institute for Artificial Intelligent Systems, University of Johannesburg, Auckland Park
来源
Intelligent Systems with Applications | 2025年 / 26卷
关键词
Fragment-based drug discovery; Generative model; Hypertension; Machine learning;
D O I
10.1016/j.iswa.2025.200508
中图分类号
学科分类号
摘要
Generative models have proven valuable in generating novel lead molecules with drug-like properties. However, beyond generating drug-like molecules, the generative model should also be able to create drug molecules with structural properties and pharmacophores to modulate a specific disease. The molecular generation process should also address the multi-objective optimization challenge of producing molecules with the desired efficacy and minimal side effects. This may entail the generation of a diverse pool of molecules with the desired structural properties and pharmacophore, which would offer diverse options and paths to developing potential new drug candidates by prioritizing molecules that balance the desired properties that can cater to the needs of different individuals. Achieving this requires a generative model learning a large dataset of molecular instances with the desired chemical/structural properties. However, large sets of drug molecules are not readily available for many diseases as there are few known drug molecular instances for treating any disease. To address this challenge, this paper presents an in silico molecular generative framework aided by fragment-based molecules’ synthesis for generating a pool of lead molecular instances possessing structural properties and pharmacophores to treat a disease of interest. The operation of the framework is explored using Hypertension as the disease of interest and beta-blocker as the reference hypertension drug to be generated. We generated over 123 beta-blocker-like molecules and further virtual-screened them for drug-likeness, docking probability, scaffold diversity, electrostatic complementarity, and synthesis accessibility to arrive at the final lead beta-blocker-like molecules. © 2025 The Author(s)
引用
收藏
相关论文
共 41 条
  • [1] Hughes J.P., Rees S.S., Kalindjian S.B., Philpott K.L., Principles of early drug discovery, British Journal of Pharmacology, 162, 6, (2011)
  • [2] Dobson C.M., Chemical space and biology, Nature, 432, 7019, (2004)
  • [3] Walters W.P., Stahl M.T., Murcko M.A., Virtual screening - an overview, Drug Discovery Today, 3, 4, (1998)
  • [4] Martinelli D.D., Generative machine learning for de novo drug discovery: A systematic review, Computers in Biology and Medicine, 145, (2022)
  • [5] Zhavoronkov A., Et al., Deep learning enables rapid identification of potent DDR1 kinase inhibitors, Nature Biotechnology, 37, 9, (2019)
  • [6] Vogt M., Exploring chemical space — Generative models and their evaluation, Artificial Intelligence in the Life Sciences, 3, (2023)
  • [7] Chamikara M.A.P., Chen Y.P.P., MedFused: A framework to discover the relationships between drug chemical functional group impacts and side effects, Computers in Biology and Medicine, 133, (2021)
  • [8] Bilodeau C., Jin W., Jaakkola T., Barzilay R., Jensen K.F., Generative models for molecular discovery: Recent advances and challenges, Wiley Interdisciplinary Reviews: Computational Molecular Science, 12, 5, (2022)
  • [9] Merk D., Friedrich L., Grisoni F., Schneider G., De novo design of bioactive small molecules by artificial intelligence, Molecular Informatics, 37, 1, (2018)
  • [10] Krishnan S.R., Bung N., Bulusu G., Roy A., Accelerating de novo drug design against novel proteins using Deep learning, Journal of Chemical Information and Modeling, 61, 2, (2021)